Physician profile
Robert S Singal
NPI 1275504847
$26,616.49
in general payments reported to CMS, 2019-2025
33 companies · $2,854 in 2025
The $2,854 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,974 · 2020: $3,556 · 2021: $3,491 · 2022: $1,579 · 2023: $2,629 · 2024: $2,532 · 2025: $2,854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,541 · Travel and Lodging: $475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,540.56 |
| Travel and Lodging | $474.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $9,957.04 | 2019-2025 | |
| Abbott Laboratories | $5,393.83 | 2019-2025 | Aveir, Jot Dx |
| Medtronic, INC. | $4,939.36 | 2021-2025 | Cobalt Dr Mri Surescan, Micra, Linq II |
| Boston Scientific Corporation | $1,029.27 | 2022-2025 | Watchman Access System, Watchman Flx, Watchman |
| Boehringer Ingelheim Pharmaceuticals, INC. | $763.11 | 2021-2024 | Jardiance |
| Amgen INC. | $606.32 | 2019-2025 | Repatha |
| Inari Medical, INC. | $539.30 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| E.R. Squibb & Sons, L.L.C. | $343.39 | 2021-2025 | Camzyos, Eliquis |
| Atricure, INC. | $341.25 | 2019-2024 | |
| Abiomed | $315.11 | 2021-2024 | Impella |
| Merck Sharp & Dohme LLC | $290.85 | 2021-2025 | Verquvo, Capvaxive |
| Janssen Pharmaceuticals, INC | $289.58 | 2019-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $281.55 | 2019-2023 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $230.14 | 2019-2025 | Farxiga |
| Cardiovascular Systems INC. | $188.79 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $186.20 | 2022-2024 | |
| Terumo Medical Corporation | $156.85 | 2025 | R2p Misago |
| Pfizer INC. | $112.57 | 2019-2025 | |
| Novo Nordisk INC | $108.95 | 2021-2025 | Ozempic, Rybelsus |
| Edwards Lifesciences Corporation | $98.00 | 2019 | |
| Penumbra, INC. | $83.62 | 2021 | |
| Cvrx, INC. | $81.04 | 2022-2024 | Barostim Neo System |
| Regeneron Healthcare Solutions, INC. | $57.94 | 2019 | |
| Cordis US Corp. | $45.47 | 2022-2023 | Mynxgrip |
| Janssen Scientific Affairs, LLC | $25.63 | 2023 | Xarelto |
| Kiniksa Pharmaceuticals International, Plc | $25.33 | 2024 | Arcalyst |
| Vifor Pharma, INC. | $21.33 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.15 | 2019 | |
| Preventice Services, LLC | $18.75 | 2021 | |
| Impulse Dynamics (USA) INC. | $18.16 | 2021 | |
| Baxter Healthcare | $16.91 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Vital Connect, INC | $15.99 | 2025 | Vitalpatch Rtm |
| Glaxosmithkline, LLC. | $15.71 | 2025 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Singal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.